EUVIMEDEUVIMED entdecken
Crossref

Efficacy and Safety of Selective RET Inhibitors in Patients with Advanced Hereditary Medullary Thyroid Carcinoma

Sarah Hamidi iD, Sireesha Yedururi, Mimi I Hu, Naifa L Busaidy, Steven I Sherman, Camilo Jimenez, Elizabeth G Grubbs, Anastasios Maniakas iD, Mark E Zafereo iD, Vivek Subbiah iD, Steven G Waguespack iD

Thyroid® · 2025

DOI: 10.1089/thy.2024.0495 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thyroid®, 2025. Verfasst von Sarah Hamidi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Proto-Oncogene Proteins c-ret, Carcinoma, Neuroendocrine, Multiple Endocrine Neoplasia Type 2a. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Two selective RET inhibitors (RETis) are effective in treating RE arranged during T ransfection ( RET )-altered medullary thyroid carcinoma (MTC), but clinical trials did not distinguish responses between hereditary MTC (hMTC) and sporadic MTC (sMTC) cases. We reviewed our single-center experience using a RETi to treat advanced hMTC.

Methods

We conducted a retrospective cohort study of patients with hMTC treated with a selective RETi at a tertiary cancer center. The primary outcome was overall response rate using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Secondary end points included overall survival (OS), progression-free survival (PFS), biochemical response rate, and safety.

Results

We identified 23 evaluable patients as follows: 15 (65%) multiple endocrine neoplasia (MEN)2A and 8 (35%) MEN2B. Median age at start of RETi was 51 years (range, 15–79). All patients had distant metastases, and 52% (12/23) had received prior systemic therapy (median = 1, range, 0–3). Patients were treated with selpercatinib ( n = 13) or pralsetinib ( n = 10), 57% (13/23) within a clinical trial. Median duration of RETi was 25 months (range, 3–72) with 11/23 (48%) patients remaining on drug at data cutoff due to an ongoing response. Median duration of follow-up was 49 months (range, 9–72). Best radiographical response was partial response in 18 (78%) and stable disease in 5 (22%) patients. Median OS was 51 months (confidence interval, 40.5–61.3); median PFS was not reached. Most common adverse events (AEs) were increased alanine aminotransferase (ALT) (48%) and aspartate aminotransferase (26%), dry mouth (39%), QT interval prolongation (39%), fatigue (35%), and hypertension (26%). AEs led to dose reductions in eight (35%) patients. No grade 5 treatment-related AEs occurred. While the germline nature of the RET pathogenic variant in hMTC could hypothetically result in increased drug-related toxicity, the incidence of most AEs, other than grade 1–2 ALT elevation and QT interval prolongation, was comparable to published clinical trials.

Conclusions

In patients with advanced hMTC, selective RETis appear safe and effective with outcomes similar to clinical trial cohorts, which mostly comprised patients with sMTC. Duration of response and AE profile was similar to sMTC, although longer follow-up and larger patient numbers are needed to confirm this.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsProto-Oncogene Proteins c-retCarcinoma, NeuroendocrineMultiple Endocrine Neoplasia Type 2aCarcinoma, MedullaryProtein Kinase InhibitorsPyrazolesMultiple Endocrine Neoplasia Type 2bHumansMiddle AgedFemaleMaleAdultAgedRetrospective StudiesAdolescentYoung AdultTreatment OutcomePyridinesProgression-Free SurvivalPyrimidines

Stichwörter der Autor:innen

RET tyrosine kinaseadverse eventsmultiple endocrine neoplasia type 2pralsetinibresistanceselpercatinib

Substanzen

Proto-Oncogene Proteins c-retRET protein, humanProtein Kinase InhibitorsPyrazolesPyridinespralsetinibselpercatinibPyrimidines

Autor:innen und Institutionen

  • Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Abdominal Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

ORCID-Profile: Sarah Hamidi, Anastasios Maniakas, Mark E Zafereo, Vivek Subbiah, Steven G Waguespack

Zitieren

APA

Hamidi, S., Yedururi, S., Hu, M. I., Busaidy, N. L., Sherman, S. I., Jimenez, C., Grubbs, E. G., Maniakas, A., Zafereo, M. E., Subbiah, V., & Waguespack, S. G. (2025). Efficacy and Safety of Selective RET Inhibitors in Patients with Advanced Hereditary Medullary Thyroid Carcinoma. Thyroid®. https://doi.org/10.1089/thy.2024.0495

Vancouver

Hamidi S, Yedururi S, Hu MI, Busaidy NL, Sherman SI, Jimenez C, et al. Efficacy and Safety of Selective RET Inhibitors in Patients with Advanced Hereditary Medullary Thyroid Carcinoma. Thyroid®. 2025. doi:10.1089/thy.2024.0495

BibTeX
@article{Hamidi2025,
  author = {Hamidi, Sarah and Yedururi, Sireesha and Hu, Mimi I and Busaidy, Naifa L and Sherman, Steven I and Jimenez, Camilo and Grubbs, Elizabeth G and Maniakas, Anastasios and Zafereo, Mark E and Subbiah, Vivek and Waguespack, Steven G},
  title = {Efficacy and Safety of Selective RET Inhibitors in Patients with Advanced Hereditary Medullary Thyroid Carcinoma},
  journal = {Thyroid®},
  year = {2025},
  doi = {10.1089/thy.2024.0495}
}
Kostenlos starten →